Evogene Ltd. has announced a warrant inducement agreement with an existing institutional investor, resulting in the immediate exercise of August 2024 Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares each. The warrants were exercised at a reduced price of $1.00 per share, generating approximately $3.4 million in gross proceeds for the company before fees and expenses. In return, the investor will receive new Series A-1 and Series B-1 unregistered warrants to purchase up to 2,538,462 ordinary shares each, with exercise prices of $1.25 per share. The new warrants will be immediately exercisable, with the Series A-1 warrants expiring in five years and the Series B-1 warrants expiring in eighteen months. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84992) on February 10, 2026, and is solely responsible for the information contained therein.